Planatome

Executive Summary

Planatome is a preclinical-stage medical device company pioneering semiconductor-inspired nano-polishing technology for surgical instruments. Its platform transforms conventional stainless steel blades into ultra-smooth, nano-polished tools that reduce tissue drag and trauma during incisions. The technology aims to accelerate wound healing, minimize scar formation, and improve clinical outcomes across a range of surgical procedures, including general surgery, dermatology, and ophthalmology. By enhancing precision and reducing inflammation, Planatome's blades could lower healthcare costs through shorter recovery times and fewer complications. Founded in 2021 and headquartered in San Francisco, the company has not yet disclosed funding rounds or valuation and appears to be in early development, focusing on product refinement and initial regulatory pathways. Its approach is differentiated from competitors like Alcon and BD by leveraging advanced materials science rather than blade coatings or geometry modifications. Planatome's success hinges on demonstrating clinical superiority in well-controlled studies and securing FDA 510(k) clearance, after which it could partner with surgical device distributors or be acquired by larger medtech firms. The company's intellectual property around nano-polishing methods and blade design could provide a durable competitive advantage if validated.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for first product (general surgery blade)45% success
• Q3 2026Publication of preclinical study results showing reduced scarring and faster healing70% success
• Q1 2027Partnership or distribution agreement with a major surgical device manufacturer30% success